Post-transplant lymphoproliferative disorders in lung transplant recipients: 20-yr experience at the University of Minnesota
- 16 November 2010
- journal article
- clinical trial
- Published by Wiley in Clinical Transplantation
- Vol. 25 (5), 705-713
- https://doi.org/10.1111/j.1399-0012.2010.01332.x
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative diseaseHaematologica, 2007
- Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trialBlood, 2007
- B-cell Posttransplant Lymphoproliferative Disorders in Heart and/or Lungs Recipients: Clinical and Molecular-Histogenetic Study of 17 Cases from a Single InstitutionTransplantation, 2006
- Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remissionClinical Transplantation, 2006
- Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantationCancer, 2005
- Lung Retransplantation After Posttransplantation Lymphoproliferative Disorder (PTLD): A Single-Center Experience and Review of Literature of PTLD in Lung Transplant RecipientsThe Journal of Heart and Lung Transplantation, 2005
- Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation1Transplantation, 2003
- The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevantCancer, 1998
- Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantationSurgery, 1996
- Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphomaCancer, 1976